Leukemia, Lymphocytic, Chronic, B-Cell: all 1,648 studies
Page 13 of 17. Open to participants first (245), then studies with results posted, then the rest; newest registration first within each.
- A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic LeukemiaWithdrawnNCT01659047Phase 2
- Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT01658319Phase 1
- Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic LeukemiaStatus unknownNCT01657955Phase 3
- CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)CompletedNCT01653717Phase 1
- Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic MalignanciesWithdrawnNCT01652014Phase 2
- A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)CompletedNCT01650727Phase 1
- Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedNCT01647971Phase 1/2
- Phase 1b Safety and Efficacy Study of TRU-016TerminatedNCT01644253Phase 1
- Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionCompletedNCT01638533Phase 1
- Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell TransplantationCompletedNCT01634217Phase 1
- A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic LeukemiaCompletedNCT01627054Phase 2
- Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction ImmunochemotherapyTerminatedNCT01625741Phase 2
- NK Cells in Cord Blood TransplantationStatus unknownNCT01619761Phase 1
- An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid TumorsCompletedNCT01618136Phase 1/2
- Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLLTerminatedNCT01612988Phase 2
- Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell TransplantationTerminatedNCT01610999Phase 1
- Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)CompletedNCT01610180Phase 2
- Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + LenalidomideTerminatedNCT01604031Phase 1
- Trial of Haploidentical Stem Cell Transplantation for Haematological CancersCompletedNCT01597219Phase 2
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
- Phase I/II Study of hLL1-DOX in Relapsed NHL and CLLTerminatedNCT01585688Phase 1/2
- A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)CompletedNCT01580228Phase 3
- Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell LymphomaCompletedNCT01567709Phase 1
- Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantWithdrawnNCT01558778Not applicable
- A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic LeukemiaCompletedNCT01558167Phase 1/2
- Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)CompletedNCT01557777Phase 2
- A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line TherapyCompletedNCT01556776Phase 3
- IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT01534715Phase 1
- Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood UnitCompletedNCT01527838Phase 1
- Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid MalignanciesCompletedNCT01523223Phase 1
- Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation TreatmentStatus unknownNCT01521689Phase 2
- The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic DiseasesTerminatedNCT01518959Phase 3
- Improving Blood Stem Cell Collection and Transplant ProceduresCompletedNCT01517035Phase 1/2
- Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-MatchTerminatedNCT01500161Phase 2
- An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic LeukemiaCompletedNCT01488162
- NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)CompletedNCT01486797Phase 2
- Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaCompletedNCT01484015Phase 1
- CD19 CAR T Cells for B Cell Malignancies After Allogeneic TransplantCompletedNCT01475058Phase 1/2
- A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL)TerminatedNCT01463852Early Phase 1
- Lipoprotein Lipase Expression in Chronic Lymphocytic LeukemiaCompletedNCT01460238
- A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic CancersCompletedNCT01460134Phase 1
- Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL)CompletedNCT01459211Phase 2
- Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic LeukemiaWithdrawnNCT01456182Phase 1
- Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell TransplantationCompletedNCT01455051Phase 2
- Phase IV Observational Study in Chronic Lymphocytic LeukemiaCompletedNCT01453062
- R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic LymphomaTerminatedNCT01446900Phase 2
- Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)Active, not recruitingNCT01446133Phase 2
- Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell TransplantationCompletedNCT01445132Phase 1
- Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)CompletedNCT01423032Phase 2/3
- Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)CompletedNCT01419691Phase 2
- Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and RituximabCompletedNCT01416974Phase 1
- Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic MalignanciesCompletedNCT01413568Phase 1/2
- Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT01410513Phase 1
- Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLLCompletedNCT01400685Phase 1
- Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological MalignanciesCompletedNCT01399840Phase 1
- Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL)CompletedNCT01397916
- Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)TerminatedNCT01397149Phase 1/2
- An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic LeukaemiaCompletedNCT01395615
- Facing Obstacles to RDI (Relative Dose Intensity) Through Telephone Intervention StrategyCompletedNCT01393366Not applicable
- Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to FludarabineCompletedNCT01392079Phase 2
- Intensified Rituimab Prephase Before FCR in Untreated B-CLLCompletedNCT01370772Phase 2
- Unrelated Donor Stem Cell TransplantationCompletedNCT01364363Not applicable
- Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.CompletedNCT01353625Phase 1
- Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and LymphomaTerminatedNCT01352312Phase 1
- Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaCompletedNCT01351935Phase 1
- Genomic Analysis of Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT01346020
- A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin LymphomaCompletedNCT01328626Phase 1
- Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT01310101Phase 2
- TXA127 in Enhancement of Engraftment in Adult Double Cord Blood TransplantationTerminatedNCT01300611Phase 1
- AMG 319 Lymphoid Malignancy FIHCompletedNCT01300026Phase 1
- Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL)Status unknownNCT01295593Phase 1/2
- A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins LymphomaCompletedNCT01290549Phase 1
- CLL Empirical Antibiotic RegimenCompletedNCT01279252Phase 2
- Nonmyeloablative Allogeneic TransplantCompletedNCT01272817Not applicable
- Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic LeukemiaWithdrawnNCT01271283Phase 2
- Antiviral Treatment of Chronic Lymphocytic LeukemiaCompletedNCT01255644Phase 4
- Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersCompletedNCT01254578Phase 1
- Azadirachta Indica in Treating Patients With Chronic Lymphocytic LeukemiaWithdrawnNCT01251250Phase 1
- Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to TreatmentCompletedNCT01246557Phase 1/2
- Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin LymphomaCompletedNCT01239875Early Phase 1
- MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
- An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)CompletedNCT01224093
- Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)CompletedNCT01212380Phase 1
- A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's LymphomaCompletedNCT01209130Phase 1
- Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
- Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic LeukemiaCompletedNCT01185262Phase 1
- High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
- T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic MalignanciesWithdrawnNCT01163201Phase 1/2
- Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic LeukemiaCompletedNCT01161511Phase 1
- RO4929097 and Capecitabine in Treating Patients With Refractory Solid TumorsCompletedNCT01158274Phase 1
- Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced LeukemiasCompletedNCT01149915Phase 1
- Biomarkers in DNA Samples From Patients With Chronic Lymphocytic Leukemia Previously Treated With Fludarabine-Based TherapyCompletedNCT01145469
- Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)CompletedNCT01144260Phase 2
- Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic LeukemiaCompletedNCT01133743Phase 2
- PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & OfatumumabWithdrawnNCT01131247Phase 2
- AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or LymphomaCompletedNCT01129193Phase 1
- RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) TrialTerminatedNCT01127542Phase 2
- Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic LeukemiaTerminatedNCT01126502Phase 1
- Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and OfatumumabTerminatedNCT01125787Phase 2
- A Study to Assess the Effect of Rifampin on the Metabolism of NavitoclaxCompletedNCT01121133Phase 1